Effective January 1st, Genentech will be updating the co-pay program benefit period. The program will be moving from a 12-month benefit to a calendar year benefit (January to December).
Patient benefit will automatically renew annually for all patients enrolled in the program on January 1st.
For more information, please call the Help Desk at 800-636-0373.
The information contained in this section of the site is intended for US specialty pharmacy representatives only. Click "OK" if you are a specialty pharmacy representative.
Complete this form when you are seeking reimbursement after paying the provider for your treatment. The instructions for using the program with these providers are included on the form.
What is ENSPRYNG?
ENSPRYNG is a prescription medicine used to treat neuromyelitis optica spectrum disorder (NMOSD) in adults who are aquaporin-4 (AQP4) antibody positive. It is not known if ENSPRYNG is safe and effective in children.
Who should not receive ENSPRYNG?
Do not take ENSPRYNG if you:
What is the most important information I should know about ENSPRYNG?
ENSPRYNG may cause serious side effects including:
What are the most common side effects of ENSPRYNG?
The most common side effects of ENSPRYNG include:
These are not all the possible side effects of ENSPRYNG.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to Genentech at 1-888-835-2555.
For more information, go to www.ENSPRYNG.com or call 1-844-NSPRYNG.